SAN JOSE, Calif.--(BUSINESS WIRE)--Micrus Endovascular Corporation (Nasdaq: MEND) today announced receipt of Shonin approval from the Ministry of Health, Labour and Welfare (MHLW) to market in Japan its Cerecyte® microcoil product line, including the MicruSphere®, Presidio®, HeliPaq® and UltiPaq® Cerecyte embolic coils, for the endovascular treatment of cerebral aneurysms. Sales of the Company’s Cerecyte microcoils will be managed by Goodman Co., Ltd., Micrus Endovascular’s exclusive distributor in the Japanese market.
